Globe News Wire
08 Dec 2025, 00:00 UTC · 41w ago
Verdict
Headline takes no side. We score HCM +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
ELUNATE, ORPATHYS, and SULANDA have been renewed for inclusion on China's National Reimbursement Drug List (NRDL) effective January 1, 2026.
More positive than 93% of claims this week
TAZVERIK has been included in the first edition of the National Commercial Health Insurance Innovative Drug List.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 86% of claims this week
ELUNATE's NRDL coverage has been expanded to include the treatment of advanced endometrial cancer with pMMR tumors in combination with TYVYT.
More positive than 77% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Multiple drugs were included or renewed on China's National Reimbursement Drug List and Commercial Insurance Drug List, significantly increasing patient access and revenue potential.
More positive than 68% of ticker scores this week
Joint developer and commercializer of ORPATHYS, which was included in the NRDL for specific lung cancer treatments.
More positive than 68% of ticker scores this week
Co-developer and co-commercializer of ELUNATE, which saw expanded coverage and renewal on the NRDL.
More positive than 53% of ticker scores this week
Holds exclusive worldwide licenses for fruquintinib outside China, benefiting from the drug's continued clinical and regulatory success.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
4h ago
More positive than 76% of relationship scores this week
[mutual] HUTCHMED and Eli Lilly co-develop and co-commercialize fruquintinib (ELUNATE) in China.
More positive than 57% of relationship scores this week
[mutual] Takeda holds the exclusive worldwide license to develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau.
+1.1%
Price agrees with the score
$14.37 vs $14.22 close before publication (Dec 5) · not market-adjusted
HCM chart →
